Infants aged 2 years or younger, pregnant women and adults aged older than 50 years qualify for an FDA-approved RSV vaccine ... us because it’s showing the effectiveness of the monoclonal ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

A single dose of the RSVPreF3 OA vaccine offers strong protection against RSV-related lower respiratory tract disease in ...

Designed to help parents understand which RSV vaccines or immunizations they are eligible for as part of Australia's new RSV Maternal and Infant Immunization Program, the guidance tool provides ...

Cumulative efficacy reached 62.9%, with protection observed against both RSV A and RSV B subtypes. Three vaccines are currently approved to prevent RSV-LRTD in people aged 60 years or older ...

The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60-74 at high risk. Credit: MargJohnsonVA/Shutterstock ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy ...

ATLANTA (AP) — A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults ... Navy and Marine Corps families with infants Richmond operator of organ ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

The US Advisory Committee on Immunization Practices (ACIP) has voted to recommend the use of respiratory syncytial virus (RSV) vaccines, including GSK's adjuvanted Arexvy, for use in the adult ...

ATLANTA (AP) — A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults ... Prevention on how regulator-cleared vaccines should be used.